Metrics to compare | TRNG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTRNGPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.6x | −2.5x | −0.5x | |
PEG Ratio | −0.52 | −0.09 | 0.00 | |
Price/Book | 1.7x | 0.0x | 2.6x | |
Price / LTM Sales | 28.9x | 12.8x | 3.0x | |
Upside (Analyst Target) | 44.4% | 233.9% | 58.6% | |
Fair Value Upside | Unlock | 2.6% | 10.2% | Unlock |
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.